Daniel W. Bowles

10.7k citations

117 papers · 3.1k indexed · 3 hit papers · h-index 30

Impact in

Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
Oncology top 2%
- Ear and Head Tumors
- Cancer-related Molecular Pathways

Papers in

Otorhinolaryngology 16
- Head and Neck Cancer Studies 16
Oncology 53
- Lung Cancer Research Studies 9
- Cancer Diagnosis and Treatment 9
- Cancer-related Molecular Pathways 8

Co-authors: Jessica D. McDermott Antonio Jimeno Sana D. Karam David Raben Bernard L. Jones Jeffrey S. Ross Laurie M. Gay Aik Choon Tan
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (12 papers)Drugs of today (11 papers)Clinical Cancer Research (8 papers)International Journal of Radiation Oncology*Biology*Physics (7 papers)
Partner nations: United States South Korea Spain

In The Last Decade

Daniel W. Bowles

112 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial 2022 · 144 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature Medicine
2021 The Lancet Oncology
2018 Clinical Cancer Research

Peers

Countries citing papers authored by Daniel W. Bowles

Since Specialization

Citations

This map shows the geographic impact of Daniel W. Bowles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel W. Bowles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel W. Bowles more than expected).

Fields of papers citing papers by Daniel W. Bowles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel W. Bowles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel W. Bowles. The network helps show where Daniel W. Bowles may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel W. Bowles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel W. Bowles Line = papers co-authored together Daniel W. Bowles links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT₃ Antagonist Antiemetic Drugs The Journal of Clinical Pharmacology ·Astria Mo’otapu, Anukul Ghimire, Wen Xia, Hailong Tang, Cathleen Doherty, Brian Buckley, Daniel W. Bowles, Cindy L. O’Bryant, Edgar A. Jaimes, Lauren M. Aleksunes, Melanie S. Joy	2024	1
2	Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Clinical Cancer Research ·Jena D. French, Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, Antoine Pécoud, Nathan R. Foster, Yuri E. Nikiforov, ez Jorge Félix Núñez Martinez, Paul J. Norman, Lori J. Wirth	2024	10
3	Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study Thyroid ·Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I. Sherman, Barbara Jarząb, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, R. Sessiz Ak, Roman M. Levytskyy, Jennifer Oliver, Bhumsuk Keam, Marcia S. Brose	2023	6
4	354O A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV+ solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) Annals of Oncology ·A. Dimitrios Colevas, Lillian L. Siu, Julia Uhrenbacher, Gourang B. Shah, Евсюков Иван Сергеевич, Saad A. Khan, Frank Hansen, C. Adrikopoulou, Victor Lee, Rhaissa Pereira Cabral, Turan Asan, Daniel W. Bowles, Renata Ferrarotto, Tatiana Lopez Areiza, Keith L. Allworth, Karen McGovern, Brigette Ma	2023	2
5	Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI) Thyroid ·Marcia S. Brose, Johannes W. A. Smit, Chia‐Chi Lin, Masayuki Tori, Daniel W. Bowles, Francis P. Worden, William F. Murray, Shih‐Ming Huang, Hui‐Jen Tsai, Maria Alevizaki, Robin P. Peeters, Shunji Takahashi, Головченко Илья Олегович, 西村武重, Nanase Okazaki, کریم حدادیان, Iwao Sugitani, Fabián Pitoia, Livia Lamartina	2022	13
6	904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort Annals of Oncology ·Alan L. Ho, Daniel W. Bowles, Caroline Even, Desirée Hao, Hyunseok Kang, Robert Metcalf, Jameel Muzaffar, Marc Oliva, Cesar A. Perez, Aron Popovtzer, Cristina P. Rodriguez, Salomon M. Stemmer, Carla M. van Herpen, Eric Winquist, Lori J. Wirth, Francis P. Worden, Bing Xia, Gary Gordon, Renata Ferrarotto	2021	6
7	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology ·Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Jolanta Krajewska, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila Hit paper breakdown →	2021	156
8	919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut) Annals of Oncology ·Renata Ferrarotto, Lori J. Wirth, Jameel Muzaffar, Cristina P. Rodriguez, Bing Xia, Cesar A. Perez, Daniel W. Bowles, Eric Winquist, Sébastien J. Hotte, Robert Metcalf, Caroline Even, Gary Gordon, Alice Y. Ho	2020	17
9	1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) Annals of Oncology ·Marcia S. Brose, Johannes W. A. Smit, C-C. Lin, Masayuki Tori, Daniel W. Bowles, Frank Worden, Todd E. Minga, PATRICIA C. BABBIT, Maria Alevizaki, Robin P. Peeters, Shunji Takahashi, Головченко Илья Олегович, Bo-Rang Park, Nanase Okazaki, کریم حدادیان, Iwao Sugitani, Fabián Pitoia, Livia Lamartina	2020	5
10	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers Clinical Cancer Research ·Nikita Pozdeyev, Laurie M. Gay, Ethan Sokol, Ryan J. Hartmaier, Kelsi E. Deaver, Stephanie Davis, Jena D. French, Pierre Vanden Borre, Daniel V. LaBarbera, Aik Choon Tan, Rebecca E. Schweppe, Lauren Fishbein, Jeffrey S. Ross, Bryan R. Haugen, Daniel W. Bowles Hit paper breakdown →	2018	374
11	Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer Clinical Cancer Research ·Sana D. Karam, Krishna Reddy, Patrick J. Blatchford, Amanda Sives, Han FH, Ayman Oweida, Hilary Somerset, Carrie B. Marshall, Christian D. Young, Kurtis D. Davies, Madeleine Kane, Aik Choon Tan, Xiaojing Wang, Antonio Jimeno, Dara L. Aisner, Daniel W. Bowles, David Raben	2018	68
12	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression Clinical Cancer Research ·Stephen B. Keysar, Justin R. Eagles, Bettina Miller, Brian C. Jackson, Farrell Epstein, 信雄矢那瀬, Ivaneide Fontes da Penha, Phuong N. Le, J. Jason Morton, Hilary Somerset, Marileila Varella‐Garcia, Aik Choon Tan, John I. Song, Daniel W. Bowles, Mary E. Reyland, Antonio Jimeno	2018	24
13	Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients European Journal of Clinical Pharmacology ·Mustafa E. Ibrahim, 範昭杉江, Yichun Hu, Susan L. Hogan, Feiyang Zeng, 英造高井, Cindy L. O’Bryant, Daniel W. Bowles, Blessy George, Wen Xia, Brian Buckley, Lauren M. Aleksunes, Melanie S. Joy	2018	29
14	Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Clinical Cancer Research ·Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella‐Garcia, Brian W. Vogler, Stephen B. Keysar, 中川洋, Dara L. Aisner, Chen Ren, Aik Choon Tan, François Wilhelm, Manoj Maniar, Sabine Eckhardt, Wells A. Messersmith, Antonio Jimeno	2014	54
15	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Jonathan H. Goldman, Sabine Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, Francis Acheampong, Hélène M. Faessel, Catherine Ayuma Ocholla, Jaime Eduardo Jaramillo Jiménez, Lee S. Rosen, Daniel W. Bowles	2014	43
16	The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Molecular Cancer Therapeutics ·Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles, Magdalena J. Glogowska, David P. Astling, J. Jason Morton, Phuong N. Le, Christina Yee, Megan Clarkson, Gregory N. Gan, Brian W. Vogler, Daniel Sehrt, Ilkhom T. Murkamilov, Dara L. Aisner, François Wilhelm, Barbara Frederick, Marileila Varella‐Garcia, Aik Choon Tan, Antonio Jimeno	2013	20
17	A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research ·David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O’Bryant, Alex Vo, Kevin Klucher, Roy S. Herbst, Sabine Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, Antonio Jimeno	2012	134
18	Vismodegib in basal cell carcinoma Drugs of today ·Rodabe N. Amaria, Daniel W. Bowles, Karl D. Lewis, Antonio Jimeno	2012	5
19	Multi-targeted tyrosine kinase inhibitors in clinical development:Focus on XL-184 (cabozantinib) Drugs of today ·Daniel W. Bowles, Elizabeth R. Kessler, Antonio Jimeno	2011	30
20	The intersection between cannabis and cancer in the United States Critical Reviews in Oncology/Hematology ·Daniel W. Bowles, Cindy L. O’Bryant, D. Ross Camidge, Antonio Jimeno	2011	52

About Daniel W. Bowles

Daniel W. Bowles is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Pathology and Forensic Medicine, having authored 117 papers that have together received 3.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Salivary Gland Tumors Diagnosis and Treatment (20 papers), Thyroid Cancer Diagnosis and Treatment (20 papers), Head and Neck Cancer Studies (16 papers), Lung Cancer Research Studies (9 papers), Cancer Diagnosis and Treatment (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Cancer-related Molecular Pathways (8 papers). The work is most often cited by research in Otorhinolaryngology (428 citations), Oncology (1.4k citations), Endocrinology, Diabetes and Metabolism (597 citations), Pulmonary and Respiratory Medicine (872 citations) and Cancer Research (352 citations). Daniel W. Bowles has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Jessica D. McDermott, Antonio Jimeno, Sana D. Karam, David Raben, Bernard L. Jones, Jeffrey S. Ross, Laurie M. Gay, Aik Choon Tan, Nikita Pozdeyev and Rebecca E. Schweppe. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Drugs of today, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact